{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit of 95% CI was not estimable due to high censoring rate and lesser number of responders who progressed.","groupId":"OG000","lowerLimit":"17.4","upperLimit":"NA","value":"17.4"},{"comment":"Median and 95% CI was not estimable due to high censoring rate and lesser number of responders who progressed.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"261"}],"units":"Participants"}],"description":"DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of \\>=25% in level of serum M-protein from lowest response value and absolute increase must be \\>=0.5g/dL; Increase of \\>=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be \\>=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of \\>=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be \\>10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium \\>11.5mg/dL) that can be attributed solely to PC proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received lenalidomide at a dose of 25 milligrams (mg) orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone at a total dose of 40 mg weekly (or 20 mg weekly for participants greater than \\[\\>\\] 75 years old or with a body mass index less than \\[\\<\\] 18.5 kilograms per meter square \\[kg/m\\^2\\]).","id":"OG000","title":"Lenalidomide, Low-dose Dexamethasone (Rd)"},{"description":"Participants received daratumumab 16 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once a week during treatment cycles 1 and 2 (for 8 weeks, each 28-day cycle); every 2 weeks during treatment cycles 3 to 6 (for 16 weeks, each 28-day cycle); once only on Day 1 during treatment cycles 7 onwards (for every 4 weeks). Lenalidomide was administered at a dose of 25 mg orally on Day 1 through Day 21 of each 28-day treatment cycle and low-dose dexamethasone was administered at a total dose of 40 mg weekly (or 20 mg weekly for participants \\>75 years old or with a body mass index \\< 18.5 kg/m\\^2).","id":"OG001","title":"Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd)"}],"paramType":"MEDIAN","populationDescription":"Response-evaluable set included participants who have a confirmed diagnosis of multiple myeloma and measurable disease and must have received at least 1 administration of study treatment and have at least 1 post baseline disease assessment. Here 'N' signifies number of participants who had PR or better response.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of first documented evidence of PD (up to 21 months)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}